Kisqali® Early Breast Cancer Drug Financial Assistance Programme

Eligibility

  • Applicant should be an adult patient diagnosed with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) Stage II and III early breast cancer at high risk of recurrence#
    (# N1+; N0  (T3/4; or T2 with Grade 3; or T2 with Grade 2 and high-risk features [Ki67 ≥ 20%, Oncotype DX recurrence score ≥ 26, or other high-risk genetic markers))
  • Hold a valid Hong Kong Identity Card
  • Be under the care of private oncology clinics or private hospitals in Hong Kong
  • Provide the original invoice and receipt (or a certified true copy) for Kisqali®  issued by a private doctor in Hong Kong
    (Only invoices dated on or after 11 June 2025 will be accepted)
  • Should not be a recipient of other Kisqali® drug assistance programmes, including:
    • The Samaritan Fund under the Hospital Authority
    • Hong Kong Breast Cancer Foundation subsidy
    • St. James’ Settlement subsidy
  • Register for the programme within 6 months of initiating Kisqali® treatment
  • Submit relevant financial documentation

 

Application Method & Procedure

Applicant must visit the Hong Kong Breast Cancer Foundation in person within 6 months of starting Kisqali® treatment and bring the following documents:

  • A completed Kisqali® Early Breast Cancer Drug Financial Assistance Programme Application Form (Patients are required to declare that they have not applied for any full insurance coverage for adjuvant drug treatment of early breast cancer)
  • A referral letter from a private doctor in Hong Kong
  • A valid Hong Kong Identity Card
  • Proof of personal income from the past three months, which may include:
  1.        Bank statements
  2.        Payslips or tax documents
  3.        Proof of other income sources (e.g., rental income)
  4.        Proof of unemployment or no income

 

Review & Subsidy Details

The Hong Kong Breast Cancer Foundation will assess each application based on the following criteria:

  • The applicant’s average monthly personal income must not exceed HK$60,000
  • The applicant must have self-funded Kisqali® purchases from private healthcare providers in Hong Kong
  • Eligible applicants will receive a subsidy of HK$18,000 per 168 tablets, disbursed by cheque
  • The standard Kisqali® treatment course consists of 39 cycles, each lasting 28 days, with 42 tablets per cycle
  • The maximum subsidy covers up to 1,638 tablets; no further subsidy will be provided beyond this amount

 

Important Notes

  • Application must be submitted within 6 months of purchasing the first treatment cycle
  • The maximum subsidy amount is HK$162,000
  • This programme does not cover any medications other than Kisqali®; patients are responsible for all other treatment costs
  • In case of any dispute, the Hong Kong Breast Cancer Foundation reserves the right of final decision

 

Contact us (appointments required)

For more information about Kisqali® (Ribociclib) Early Breast Cancer Drug Financial Assistance Programme and application procedures, please contact Breast Cancer Support Centre in the Hong Kong Breast Cancer Foundation.

 

HKBCF Breast Cancer Support Centre (Hong Kong)

Address: 22/F, Jupiter Tower, 9 Jupiter Street, North

Point, Hong Kong (Exit A, Fortress Hill MTR Station)

Patient Support Hotline: (852) 2525 6033

Fax: (852) 2525 6233

 

HKBCF Jockey Club Breast Health Centre (Kowloon) 
Breast Cancer Support Centre (Kowloon Centre)

Address: 1/F, 28 Lung Cheung Road, Ngau Chi Wan,

Kowloon (Exit C2, Choi Hung MTR Station)

Patient Support Hotline: (852) 2597 3251

Fax: (852) 2597 5355